Lineage Cell Therapeutics, Inc. (LCTX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 6M 12M 18M Q3 '16: 6.1M Q4 '16: 5.9M Q1 '17: 4.2M Q2 '17: 3.3M Q3 '17: 3.5M Q4 '17: 3.3M Q1 '18: 3.7M Q2 '18: 5.9M Q3 '18: 5.2M Q4 '18: 5M Q1 '19: 5.2M Q2 '19: 3.4M Q3 '19: 3M Q4 '19: 3.5M Q1 '20: 3.1M Q2 '20: 2.7M Q3 '20: 2.7M Q4 '20: 1.8M Q1 '21: 1.7M Q2 '21: 1.8M Q3 '21: 3.5M Q4 '21: 4.3M Q1 '22: 9.2M Q2 '22: 13.2M Q3 '22: 14M Q4 '22: 14.7M Q1 '23: 11.9M Q2 '23: 10.5M Q3 '23: 8.8M Q4 '23: 8.9M Q1 '24: 8M Q2 '24: 6.2M Q3 '24: 8.7M Q4 '24: 9.5M Q1 '25: 9.6M Q2 '25: 10.9M Q3 '25: 10.8M Q4 '25: 14.6M Q1 '26: 14.8M Q2 '26: 13.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 5M 10M 15M Q1 '14: 4.1M Q2 '14: 4M Q3 '14: 4.4M Q4 '14: 4.4M Q1 '15: 4.5M Q2 '15: 5.4M Q3 '15: 6.3M Q4 '15: 5.9M Q1 '16: 6.8M Q2 '16: 6.2M Q3 '16: 5.8M Q4 '16: 5.6M Q1 '17: 4M Q2 '17: 3.3M Q3 '17: 3.4M Q4 '17: 3.3M Q1 '18: 3.5M Q2 '18: 5.6M Q3 '18: 4.9M Q4 '18: 4.7M Q1 '19: 5M Q2 '19: 3.2M Q3 '19: 2.7M Q4 '19: 3.1M Q1 '20: 2.7M Q2 '20: 2.3M Q3 '20: 2.3M Q4 '20: 1.4M Q1 '21: 1.3M Q2 '21: 1.4M Q3 '21: 2.2M Q4 '21: 2.9M Q1 '22: 7.7M Q2 '22: 11.6M Q3 '22: 13.1M Q4 '22: 14M Q1 '23: 11.2M Q2 '23: 9.9M Q3 '23: 8.3M Q4 '23: 8.3M Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23

Operating Income TTM

-75M -50M -25M 0 25M 50M 75M Q3 '16: -69.4M Q4 '16: -59M Q1 '17: -46.5M Q2 '17: -40.6M Q3 '17: -40.6M Q4 '17: -38.9M Q1 '18: -39.8M Q2 '18: -40.4M Q3 '18: -41.3M Q4 '18: -41.8M Q1 '19: -42.4M Q2 '19: -44M Q3 '19: -42.1M Q4 '19: -38.9M Q1 '20: -33.6M Q2 '20: -29.1M Q3 '20: -27.4M Q4 '20: -26.4M Q1 '21: -26.1M Q2 '21: -26.7M Q3 '21: -26.9M Q4 '21: -49.2M Q1 '22: -48.6M Q2 '22: -45.7M Q3 '22: -44.1M Q4 '22: -22.5M Q1 '23: -22.8M Q2 '23: -23.6M Q3 '23: -25M Q4 '23: -24.7M Q1 '24: -24.8M Q2 '24: -25.6M Q3 '24: -22.7M Q4 '24: -21.5M Q1 '25: -21.3M Q2 '25: -35.2M Q3 '25: -35.2M Q4 '25: -36.6M Q1 '26: -37.7M Q2 '26: -26.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: 25.1M Q4 '16: 33.7M Q1 '17: 100.1M Q2 '17: 63.9M Q3 '17: 47M Q4 '17: -20M Q1 '18: -132.8M Q2 '18: -125.4M Q3 '18: -73M Q4 '18: -46M Q1 '19: 56.9M Q2 '19: 31.1M Q3 '19: -52.2M Q4 '19: -11.7M Q1 '20: -59.4M Q2 '20: -35.9M Q3 '20: -27.2M Q4 '20: -20.6M Q1 '21: -13.7M Q2 '21: -11.9M Q3 '21: -12M Q4 '21: -43M Q1 '22: -48.7M Q2 '22: -50.7M Q3 '22: -48.9M Q4 '22: -26.3M Q1 '23: -23.6M Q2 '23: -22M Q3 '23: -23.1M Q4 '23: -21.5M Q1 '24: -23.7M Q2 '24: -24.2M Q3 '24: -20.1M Q4 '24: -18.6M Q1 '25: -16.2M Q2 '25: -40.9M Q3 '25: -67.7M Q4 '25: -63.5M Q1 '26: -64.2M Q2 '26: -32.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 600K 1.2M 1.8M Q2 '14: 813.4K Q3 '14: 837.7K Q4 '14: 837.9K Q1 '15: 970K Q2 '15: 978K Q3 '15: 1.2M Q4 '15: 1.1M Q1 '16: 1.1M Q2 '16: 902K Q3 '16: 528K Q4 '17: 168K Q1 '18: 220K Q2 '18: 321K Q3 '18: 304K Q4 '18: 302K Q1 '19: 261K Q2 '19: 262K Q3 '19: 341K Q4 '19: 412K Q1 '20: 438K Q2 '20: 406K Q3 '20: 394K Q4 '20: 385K Q1 '21: 403K Q2 '21: 453K Q3 '21: 1.3M Q4 '21: 1.4M Q1 '22: 1.5M Q2 '22: 1.6M Q3 '22: 830K Q4 '22: 728K Q1 '23: 671K Q2 '23: 583K Q3 '23: 517K Q4 '23: 671K Q1 '24: 650K Q2 '24: 567K Q3 '24: 436K Q4 '24: 334K Q1 '25: 272K Q2 '15 Q3 '16 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25

Operating Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '16: -47.4M Q4 '16: -42.3M Q1 '17: -36.1M Q2 '17: -34.9M Q3 '17: -33.7M Q4 '17: -30.5M Q1 '18: -32.8M Q2 '18: -31.1M Q3 '18: -30.7M Q4 '18: -30.9M Q1 '19: -29.9M Q2 '19: -32.1M Q3 '19: -32.2M Q4 '19: -31.9M Q1 '20: -27.7M Q2 '20: -22.2M Q3 '20: -19.6M Q4 '20: -19.8M Q1 '21: -22.2M Q2 '21: -23.3M Q3 '21: -23.3M Q4 '21: -23.6M Q1 '22: 5.8M Q2 '22: 4.1M Q3 '22: 3.5M Q4 '22: 1.1M Q1 '23: -32.1M Q2 '23: -31.3M Q3 '23: -30.9M Q4 '23: -28.6M Q1 '24: -23.1M Q2 '24: -22M Q3 '24: -22.8M Q4 '24: -23.1M Q1 '25: -22.2M Q2 '25: -22.6M Q3 '25: -20.4M Q4 '25: -18.9M Q1 '26: -22.1M Q2 '26: -23.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-60M -40M -20M 0 20M 40M 60M Q3 '16: -50M Q4 '16: -44.6M Q1 '17: -38M Q2 '17: -36.3M Q3 '17: -35M Q4 '17: -31.8M Q1 '18: -34.1M Q2 '18: -32.2M Q3 '18: -31.5M Q4 '18: -31.4M Q1 '19: -30.4M Q2 '19: -32.8M Q3 '19: -32.8M Q4 '19: -32.4M Q1 '20: -27.9M Q2 '20: -22.3M Q3 '20: -19.7M Q4 '20: -19.8M Q1 '21: -22.2M Q2 '21: -23.5M Q3 '21: -23.5M Q4 '21: -23.9M Q1 '22: 5.4M Q2 '22: 3.8M Q3 '22: 2.9M Q4 '22: 646K Q1 '23: -32.6M Q2 '23: -32M Q3 '23: -31.4M Q4 '23: -29.2M Q1 '24: -23.6M Q2 '24: -22.3M Q3 '24: -23.1M Q4 '24: -23.7M Q1 '25: -22.8M Q2 '25: -23.1M Q3 '25: -20.9M Q4 '25: -19.4M Q1 '26: -22.6M Q2 '26: -24.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 90M 180M 270M Q2 '15: 78.4K Q3 '15: 79.2K Q1 '16: 90.4K Q2 '16: 95.8K Q3 '16: 103.6K Q1 '17: 107.4K Q2 '17: 110.9M Q3 '17: 115.3M Q1 '18: 126.9M Q2 '18: 126.9M Q3 '18: 127M Q1 '19: 132.9M Q2 '19: 149.6M Q3 '19: 149.7M Q1 '20: 149.8M Q2 '20: 149.8K Q3 '20: 150M Q1 '21: 158.7K Q2 '21: 162.9M Q3 '21: 167.6M Q1 '22: 169.6M Q2 '22: 169.7M Q3 '22: 169.8M Q1 '23: 170.1M Q2 '23: 170.6M Q3 '23: 174.9M Q1 '24: 182.9M Q2 '24: 188.8M Q3 '24: 188.8M Q1 '25: 226.1M Q2 '25: 228.4M Q3 '25: 228.9M Q1 '26: 261.2M Q2 '26: 261.5M Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.20 -0.80 -0.40 0.00 0.40 0.80 1.20 Q4 '10: -0.28 Q1 '11: -0.30 Q2 '11: -0.33 Q3 '11: -0.30 Q4 '11: -0.34 Q1 '12: -0.37 Q2 '12: -0.39 Q3 '12: -0.41 Q4 '12: -0.43 Q1 '13: -0.48 Q2 '13: -0.51 Q3 '13: -0.57 Q3 '14: -0.78 Q4 '14: -0.56 Q1 '18: -1.07 Q2 '18: -0.99 Q3 '18: -0.58 Q4 '18: -0.36 Q1 '19: 0.44 Q2 '19: 0.27 Q3 '19: -0.37 Q4 '19: -0.04 Q1 '20: -0.40 Q1 '22: -0.29 Q2 '22: -0.30 Q3 '22: -0.29 Q4 '22: -0.15 Q1 '23: -0.14 Q2 '23: -0.13 Q3 '23: -0.13 Q4 '23: -0.13 Q1 '24: -0.14 Q2 '24: -0.14 Q3 '24: -0.12 Q4 '24: -0.10 Q1 '25: -0.08 Q2 '25: -0.18 Q3 '25: -0.29 Q4 '25: -0.28 Q1 '26: -0.29 Q4 '11 Q1 '13 Q1 '18 Q2 '19 Q2 '22 Q3 '23 Q4 '24 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.